Mycoplasma testing for stem cells is a critical quality control measure that detects hidden microbial contamination in stem cell cultures, protecting both research integrity and the safety of cell-based therapies. Because mycoplasmas lack a cell wall, pass through standard sterilizing filters, and silently alter stem cell proliferation, differentiation, and genomic stability, routine examination in accordance with pharmacopoeial and ISO standards is essential for any laboratory working with stem cells. This article outlines sample types, testing items, detection methods, regulatory requirements, and practical considerations for mycoplasma examination of stem cell products.
Technical Overview
Mycoplasmas are the smallest known self-replicating microorganisms, typically measuring 0.1 to 0.3 micrometers. They are wall-free prokaryotes that lack a peptidoglycan cell wall, which makes them invisible under standard light microscopy, resistant to beta-lactam antibiotics, and capable of passing through 0.22 micrometer sterilizing filters. Surveys of research laboratories worldwide indicate that 15 to 35 percent of continuous cell cultures are contaminated with mycoplasma, making it one of the most pervasive and underestimated problems in cell culture.
For stem cell applications, mycoplasma contamination is particularly damaging. Contamination can alter cellular metabolism, chromosome stability, gene expression profiles, cytokine secretion, growth kinetics, and, most critically for stem cells, proliferation capacity and differentiation potential. Because contaminated cultures often show no visible turbidity or cytopathic effect, contamination is frequently discovered only after experimental data have been compromised or after a cell therapy batch has failed release testing.
The most common contaminating species in cell culture include the following:
- Mycoplasma orale, frequently of human oral origin from operators
- Mycoplasma hyorhinis, commonly introduced through animal-derived reagents
- Mycoplasma arginini, associated with bovine serum and culture supplements
- Mycoplasma fermentans and Mycoplasma salivarium, of human respiratory origin
- Mycoplasma hominis, isolated from primary human tissues and operator contact
- Acholeplasma laidlawii, introduced through serum and other bovine-derived materials
Recognizing these risks, regulatory authorities and compendial bodies require mycoplasma testing at multiple stages of stem cell work. Key references include USP General Chapter 63 (Mycoplasma Tests), the European Pharmacopoeia section 2.6.7 (Mycoplasmas), the Japanese Pharmacopoeia, ICH Q5D on cell substrates, and regional guidance documents from major regulatory agencies governing cell and gene therapy products. Testing performed by accredited third-party laboratories to ISO/IEC 17025 requirements provides the independent documentation needed for research publications, IND submissions, and GMP batch release.
Testing Samples
Stem Cell Culture Supernatant
Spent culture medium collected from actively growing stem cell cultures is the most common and most informative sample type. Mycoplasmas are predominantly extracellular organisms that colonize the cell surface and are shed into the medium, so the supernatant typically carries a higher organism load than the cells themselves. Recommended practice is to collect 1 to 2 milliliters of supernatant from cultures that have been maintained without antibiotics for at least several passages and have reached 70 to 90 percent confluence, ensuring the culture has been in contact with the medium long enough for organisms to accumulate.
Cell Suspensions and Banked Cells
Master cell banks, working cell banks, and primary stem cell stocks, including human embryonic stem cells, induced pluripotent stem cells, and mesenchymal stromal cells, should be tested before release for use. Both the cell pellet and the cryopreservation supernatant can be examined. Testing at the bank level establishes a contamination-free starting point and satisfies the expectation of ICH Q5D that cell substrates be free of adventitious agents.
Harvest Materials and Final Cell Therapy Products
For clinical-grade stem cell products, mycoplasma testing is a mandatory release assay performed on the final harvest or on the formulated product prior to release for administration. Because many cell therapy products have short shelf lives and compendial culture methods take up to 28 days, rapid validated nucleic acid amplification methods are widely used for lot release, with appropriate risk mitigation strategies agreed upon with regulators.
Culture Reagents and Ancillary Materials
Fetal bovine serum, basal media, growth factors, dissociation enzymes, and feeder cell layers are recognized routes of mycoplasma introduction. Incoming quality control testing of these materials, particularly serum lots before acceptance, is a core element of contamination prevention programs in GMP facilities and biobanks operating under ISO 20387.
Testing Items
Mycoplasma examination for stem cells can be structured as a tiered set of test items depending on the purpose, stage of the workflow, and regulatory context:
- Qualitative detection, reported as mycoplasma detected or not detected, which is the standard test item for routine monitoring and batch release
- Quantitative enumeration, expressed as colony forming units per milliliter or genome copies per milliliter, useful for contamination investigation and method validation
- Species identification through sequencing of the 16S rRNA gene or other marker regions, valuable for tracing the contamination source to an operator, reagent, or cross-contaminated culture
- Screening for related wall-free prokaryotes, including Acholeplasma and Spiroplasma species, as required by compendial methods for certain materials
- Method suitability and validation studies, demonstrating that the sample matrix does not inhibit detection and that the analytical procedure meets compendial sensitivity requirements
Testing Methods
Several complementary technologies are available, each with distinct advantages in sensitivity, turnaround time, and regulatory acceptance. The choice of method should reflect the intended use, whether routine research surveillance, cell bank qualification, or GMP product release.
Culture Method (Compendial Reference Method)
The traditional culture method described in USP 63 and European Pharmacopoeia 2.6.7 remains the regulatory reference. It involves inoculating both liquid broth and agar media, incubating for up to 14 days for direct detection, and simultaneously using an indicator cell culture (such as Vero or NIH 3T3 cells) followed by DNA staining for the indirect detection of non-cultivable strains. The full procedure extends to approximately 28 days. The method can detect mycoplasma levels as low as 10 colony forming units per milliliter for the reference strain panel, but its length limits its practicality for short-shelf-life products.
Polymerase Chain Reaction (PCR and qPCR)
Nucleic acid amplification targeting conserved regions of the mycoplasmal 16S rRNA gene, 16S-23S intergenic spacer, or conserved housekeeping genes has become the workhorse of modern mycoplasma testing. Conventional endpoint PCR followed by gel electrophoresis, as well as real-time quantitative PCR with fluorescent probes, delivers results within a few hours with a typical analytical sensitivity of approximately 10 to 100 colony forming units per milliliter of sample. Compendial authorities permit PCR as an alternative method provided it is validated for sensitivity, specificity, and robustness against the reference panel of mycoplasma species. Advantages include high throughput, low sample volume requirements, and direct applicability to complex matrices such as serum-containing media and cryopreservation solutions.
DNA Fluorochrome Staining
The indicator cell DNA staining method uses fluorochromes such as Hoechst 33258 or DAPI that bind to AT-rich DNA. Vero or 3T3 indicator cells are inoculated with the test sample, incubated for several days, then fixed and stained. Mycoplasmal DNA appears as fine punctate or filamentous fluorescence around the eukaryotic nuclei, indicating contamination. The method is simple and inexpensive but requires experienced analysts, suffers from subjective interpretation, and can miss low-level contamination or non-cultivable organisms growing poorly on indicator cells.
Rapid Enzymatic and Bioluminescence Assays
Commercially available biochemical assays detect mycoplasma-specific enzymatic activities absent from eukaryotic cells, such as enzymes involved in mycoplasmal energy metabolism detected through luminescent or colorimetric readouts. These assays return results in 20 minutes to a few hours and are well suited to high-frequency routine screening between PCR confirmations. Their sensitivity is generally somewhat lower than PCR, so they are best positioned as rapid surveillance tools rather than sole release assays.
Next-Generation Sequencing and Metagenomic Screening
Shotgun metagenomic sequencing and broad-range 16S amplicon sequencing can reveal the entire microbial landscape of a culture, including fastidious or non-cultivable mycoplasma species and unexpected bacterial contaminants. Although currently more common in characterization and contamination investigation than in routine release testing, NGS is increasingly used for advanced cell therapy development under ICH Q5A and Q5D risk assessment frameworks.
Method Validation and Compendial Equivalence
Regardless of the technology selected, methods used for regulated stem cell products must be validated. Validation parameters include limit of detection, specificity against a panel of relevant mycoplasma reference strains, robustness across operators and reagent lots, interference testing in the actual product matrix, and, for alternative methods, demonstrated comparability to the compendial culture procedure. Accredited third-party laboratories routinely provide these validation packages to support regulatory submissions.
Applications
Mycoplasma examination of stem cells serves distinct purposes across the research, development, and manufacturing continuum:
- Research laboratory quality assurance, ensuring that published data on stem cell self-renewal, differentiation, and molecular signatures are not confounded by hidden contamination
- Cell bank qualification and periodic monitoring, securing master and working banks of embryonic stem cells, induced pluripotent stem cells, and mesenchymal stromal cells
- GMP batch release testing for stem cell therapies, exosome products, and derived biologics prior to clinical administration
- Regulatory dossier support for IND and marketing authorization submissions, including data generated by accredited third-party laboratories under ISO/IEC 17025 quality systems
- Contamination outbreak investigation, combining species-level identification with environmental and operator sampling to trace the root cause
- Vendor and incoming material qualification, particularly for serum, media, and ancillary reagents used in stem cell manufacturing
Typical testing frequency recommendations include testing at the establishment of each new culture line, at cell bank creation, monthly or at least quarterly for actively used research cultures, and at every harvest for clinical products. Facilities should also test after any suspected contamination event, after receipt of new cell lines from external sources, and before cryopreservation of valuable clones.
FAQ
Why does routine sterility testing fail to detect mycoplasma?
Standard sterility tests use bacteriological media designed for fastidious but conventional bacteria and rely on visible turbidity. Mycoplasmas grow slowly, often do not produce turbidity in these media, and many strains will not grow at all under standard sterility test conditions. Specialized mycoplasma broths, agar formulations, indicator cell systems, or molecular assays are required for reliable detection.
How often should stem cell cultures be tested?
For research laboratories, testing every one to three months for actively cultured lines is a widely accepted practice, with additional testing when new lines are introduced or results from other cultures in the same incubator turn positive. For GMP manufacturing, testing is required at cell bank qualification and on each product lot at harvest or final fill, following the approved control strategy.
What sample volume and handling conditions are required?
For PCR-based testing, 0.5 to 2 milliliters of culture supernatant is typically sufficient. Samples should be collected aseptically, transported chilled at 2 to 8 degrees Celsius, and tested within 24 to 48 hours, or frozen at minus 20 degrees Celsius or below for longer storage. Cultures should ideally be antibiotic-free for at least two weeks before sampling to allow organism loads to rebound and avoid false negatives.
What is the difference in sensitivity between PCR and the culture method?
A well-validated PCR assay can detect approximately 10 to 100 colony forming units per milliliter within hours, whereas the compendial culture method requires up to 28 days but, when performed correctly, can detect approximately 10 colony forming units per milliliter for the reference strain panel. The two methods are complementary: PCR offers speed and convenience, while the culture method remains the regulatory reference for demonstrating alternative method equivalence.
How should discrepant results between methods be interpreted?
A PCR-positive, culture-negative result may reflect non-viable organisms, residual DNA from reagents, low-level contamination below culture detection thresholds, or, rarely, PCR inhibition artifacts. Confirmation through an orthogonal method, an independent extraction, species-level sequencing, or retesting after a short antibiotic-free culture interval is recommended before a final disposition is made for valuable cultures or clinical batches.
Can a contaminated stem cell culture be rescued?
Treatment with quinolone, tetracycline, or macrolide-class antibiotic cocktails, or combinations such as pleuromutilin-based regimens, can eliminate mycoplasma from valuable cultures in many cases. However, elimination requires several weeks of treatment followed by repeated testing to confirm clearance, and for clinical-grade materials, most quality systems prohibit rescue of contaminated banks, requiring instead that a clean bank be re-derived and re-qualified.